查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004130

人工心臟瓣膜市場：按瓣膜類型、手術方法、應用和最終用戶分類－2026-2032年全球市場預測

Prosthetic Heart Valves Market by Valve Type, Procedure, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人工心臟瓣膜市場價值將達到 126.2 億美元，到 2026 年將成長至 141.9 億美元，到 2032 年將達到 277.6 億美元，年複合成長率為 11.91%。

主要市場統計數據
基準年 2025 126.2億美元
預計年份：2026年 141.9億美元
預測年份 2032 277.6億美元
複合年成長率 (%) 11.91%

本文全面說明了正在重塑人工心臟瓣膜生態系統的臨床因素、技術進步和相關人員趨勢。

人工心臟瓣膜領域融合了外科傳統和微創醫療創新，並受到臨床需求、人口結構變化和器材技術進步的影響。瓣膜工程和輸送系統的進步正在為各個年齡層的患者拓展治療選擇，從而引發臨床醫生、醫院管理者和保險公司之間更加多方面的討論。隨著治療方法的不斷發展，製造商和醫療保健系統面臨的營運和監管要求也隨之改變，因此需要重新評估證據產生、供應鏈韌性和上市後監測策略。

對外科創新、導管治療方法的擴展、材料科學以及對價值醫療的需求所驅動的變革性變化進行詳細分析。

人工心臟瓣膜領域正經歷著一場變革，其驅動力包括手術技術的創新、材料科學的突破以及對以患者為中心的治療效果的日益重視。經導管瓣膜置換術正迅速走向成熟，適應症不斷擴大，手術安全性也得到提升。同時，瓣膜支架幾何形狀和瓣膜材料的迭代改進正在增強瓣膜的耐久性和血流動力學性能。這些技術進步伴隨著影像、導航和輸送導管的創新，共同降低了手術操作的變異性，並拓展了進入複雜解剖結構的途徑。

本文探討了美國關稅政策和貿易結構調整的變化如何影響人工心臟瓣膜產業相關人員的採購、定價和供應鏈策略。

預期中的關稅調整和貿易政策重組將為人工心臟瓣膜行業相關人員的採購、定價和全球供應鏈策略帶來新的複雜性。關稅體系的變化可能會改變進口零件、成品及相關一次性產品的成本結構，迫使製造商重新評估其採購和製造地的選址。積極的策略因應措施包括重新檢視供應商合約、探索近岸外包方案以及垂直整合機會，以在確保關鍵投入品供應的同時，緩解利潤率下降的局面。

深入的細分分析揭示了瓣膜類型、手術途徑、臨床應用和最終用戶趨勢如何決定專業商業和臨床策略。

基於細分市場的洞察揭示了每種瓣膜類型、治療途徑、臨床應用和終端用戶環境的不同機會和策略重點。在評估瓣膜類型時，機械瓣膜（包括雙葉瓣、籠式球瓣和傾斜盤瓣）展現出獨特的臨床特徵，這些特徵會影響後續護理和抗凝血治療管理。生物瓣膜（包括牛瓣膜、同種異體瓣膜和豬源瓣膜）優先考慮生物相容性，並提供可減少長期抗凝血治療需求的替代方案。這些器械特有的差異需要產生個人化的證據並進行臨床醫生教育，以支持合適的病患選擇和長期管理路徑。

對美洲、歐洲、中東、非洲和亞太地區的監管複雜性、採用促進因素和商業化路徑進行全面的區域性分析。

區域趨勢是監管時間表、應用率和商業模式的關鍵促進因素，從而在美洲、歐洲、中東和非洲以及亞太地區形成了不同的市場路徑。在美洲，成熟的臨床生態系統和完善的報銷體係正在推動創新瓣膜技術的快速應用，同時，醫療保健系統也日益重視療效和成本效益，並將其作為指導採購指南的依據。同時，歐洲、中東和非洲（EMEA）市場的特點是監管環境各異，支付方組成也多種多樣，因此需要製定細緻的打入市場策略，並利用本地化的臨床證據來支持各子區域的市場應用。

詳細分析領先製造商如何透過創新、夥伴關係、證據產生和卓越的供應鏈來實現差異化。

醫療設備製造商之間的競爭格局日益取決於臨床證據的整合、供應鏈的韌性以及差異化技術平台。主要企業正投資研發新一代說明書材料、增強耐久性測試以及客製化的給藥系統，以滿足尚未滿足的臨床需求並拓展適應症。與影像和導航公司建立策略夥伴關係，以及與學術機構進行合作研究，正在加速醫療設備的迭代改進，並透過培訓和指導計畫促進臨床醫生儘早採用新產品。

為設備開發商和醫療保健系統領導者提供實用建議，以協調創新、供應鏈彈性、證據生成和商業性敏捷性。

產業領導者應採取一系列切實可行的策略，使研發投資與臨床優先事項、業務永續營運和商業性靈活性保持一致。首先，應優先開發模組化瓣膜和輸送平台，以便在無需全面重新培訓操作流程的情況下進行逐步升級，從而加快臨床醫生接受度並降低生命週期成本。同時，應投資於永續的臨床前研究和真實世界證據項目，以衡量以患者為中心的療效和長期表現，從而支持醫保報銷和擴大適應症。

採用高度透明的調查方法，深入了解人工瓣膜，包括臨床醫生參與、監管分析和證據三角驗證。

本研究整合了從臨床醫生訪談、採購相關人員聽證會和器械開發商簡報中獲得的第一手信息，並結合對同行評審的臨床文獻、監管申報文件和手術最佳實踐指南的嚴格審查。主要的質性研究對象為介入性心臟病專家、心臟外科醫師、醫院採購經理和臨床試驗負責人，旨在了解他們對推廣障礙、訓練需求和手術結果的實際觀點。這些直接意見輔以對監管文件和已發布的上市後監測數據的評估，檢驗了不同瓣膜類型和手術方法的性能說明和安全性概況。

一份權威的綜合分析報告，重點闡述了將技術潛力轉化為永續臨床應用和營運韌性所必需的策略挑戰。

醫療設備的創新、手術流程的擴展以及供應鏈複雜性的增加，為人工心臟瓣膜領域的企業帶來了巨大的機會和新的風險。持續的技術進步和適應症的擴大有望改善患者預後並擴大治療覆蓋範圍，但要實現這些益處，需要嚴謹的循證策略、靈活的生產系統以及以臨床醫生為中心的推廣模式。隨著貿易政策和報銷機制的不斷演變，採取積極主動、優先考慮韌性和清晰價值主張的策略，對於保持競爭力至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人工心臟瓣膜市場（依瓣膜類型分類）

  • 機械的
    • 二尖瓣
    • 籠球
    • 傾斜盤
  • 生物瓣膜
    • 牛
    • 同種異體移植
    • 源自豬

第9章：人工心臟瓣膜市場（依手術方式分類）

  • 手術置換術
    • 微創
    • 傳統開胸手術
  • 經導管瓣膜置換術
    • 尖端入路
    • 股動脈通路

第10章：人工心臟瓣膜市場：依應用領域分類

  • 主動脈瓣
  • 二尖瓣
  • 三尖瓣

第11章 人工心臟瓣膜市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第12章 人工心臟瓣膜市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：人工心臟瓣膜市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 人工心臟瓣膜市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國人工心臟瓣膜市場

第16章：中國人工心臟瓣膜市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 4C Medical Technologies, Inc.
  • Abbott Laboratories
  • Artivion, Inc.
  • Boston Scientific Corporation
  • Braile Biomedica Industria, Comercio e Representacoes SA
  • Colibri Heart Valve, LLC
  • Corcym Srl
  • Edwards Lifesciences Corporation
  • Foldax, Inc.
  • JenaValve Technology, Inc.
  • Labcor Laboratorios Ltda.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Meril Life Sciences Private Limited
  • MicroPort CardioFlow Medtech Corporation
  • On-X Life Technologies, Inc.
  • Symetis SA
  • TTK Healthcare Limited
  • Venus Medtech Inc.
Product Code: MRR-62667ADFA787

The Prosthetic Heart Valves Market was valued at USD 12.62 billion in 2025 and is projected to grow to USD 14.19 billion in 2026, with a CAGR of 11.91%, reaching USD 27.76 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.62 billion
Estimated Year [2026] USD 14.19 billion
Forecast Year [2032] USD 27.76 billion
CAGR (%) 11.91%

Comprehensive introduction framing clinical drivers, technological advances, and stakeholder dynamics reshaping the prosthetic heart valve ecosystem

The prosthetic heart valve sector stands at the intersection of surgical tradition and minimally invasive innovation, shaped by clinical need, demographic shifts, and device technology progress. Advances in valve engineering and delivery systems have expanded therapeutic options for patients across the lifespan, driving more nuanced conversations among clinicians, hospital administrators, and payers. As therapies evolve, so too do the operational and regulatory demands on manufacturers and health systems, prompting a re-evaluation of evidence generation, supply chain resilience, and post-market surveillance strategies.

Transitioning from historical open-heart procedures toward catheter-based interventions has redefined procedural pathways and patient eligibility. Concurrently, the competing design philosophies of mechanical and tissue valves require distinct clinical and commercial approaches, influencing long-term management, follow-up requirements, and prosthesis selection criteria. These dynamics underscore the importance of an integrated perspective that links clinical outcomes, health economics, and real-world adoption patterns to inform strategic decisions across R&D, regulatory affairs, and commercial teams.

Detailed analysis of the transformative shifts driven by surgical innovation, catheter-based expansion, material science, and value-based care imperatives

The prosthetic heart valve landscape is undergoing transformative shifts driven by procedural innovation, material science breakthroughs, and an intensified focus on patient-centred outcomes. Transcatheter valve replacement technologies have matured rapidly, broadening indications and improving peri-procedural safety, while iterative refinements in valve frame geometry and leaflet materials are improving durability and haemodynamic performance. These technical improvements are accompanied by innovations in imaging, navigation, and delivery catheters, which collectively reduce procedural variability and expand access to complex anatomies.

Beyond devices, care delivery models are shifting as multidisciplinary heart teams adopt streamlined pathways that prioritise shorter hospital stays and faster functional recovery. Minimally invasive surgical approaches persist alongside catheter-based treatments, creating a dual-track paradigm where device makers must balance investments across both surgical and transcatheter portfolios. In parallel, reimbursement frameworks and value-based purchasing initiatives are placing greater emphasis on long-term outcomes, quality-of-life metrics, and total cost of care, incentivising manufacturers to demonstrate durable clinical benefit and post-market performance. Taken together, these transformative forces are reshaping competitive positioning, regulatory strategies, and clinical adoption trajectories in a market defined by rapid technological evolution and heightened expectations from clinicians and payers.

Examination of how evolving United States tariff policies and trade realignments could reshape procurement, pricing, and supply chain strategies for valve stakeholders

Anticipated tariff adjustments and trade policy realignments will introduce new layers of complexity into procurement, pricing, and global supply chain strategies for stakeholders in the prosthetic heart valve space. Changes in tariff regimes have the potential to alter cost structures for imported components, finished devices, and ancillary disposables, prompting manufacturers to reassess sourcing footprints and manufacturing allocation. A strategic and proactive response involves re-examining supplier contracts, nearshoring options, and vertical integration opportunities to mitigate margin compression while preserving access to critical inputs.

In addition to direct cost impacts, tariff-related shifts may induce changes in competitive dynamics across regional markets. Manufacturers with existing local manufacturing capabilities or favourable trade agreements will experience relative advantage in procurement discussions, whereas those reliant on cross-border supply chains may face pressure on pricing and lead times. Health systems and ambulatory surgical centres may respond by prioritising value and supply resilience in purchasing decisions, thereby elevating the importance of demonstrable total-cost-of-care benefits and reliable inventory management. Consequently, industry participants should develop flexible pricing architectures and scenario-based supply chain plans that account for tariff volatility and evolving trade policies.

Insightful segmentation analysis revealing how valve type, procedural pathway, clinical application, and end-user dynamics dictate specialised commercial and clinical strategies

Segmentation-driven insights reveal differentiated opportunities and strategic priorities across valve types, procedural channels, clinical applications, and end-user settings. When evaluating valve type, mechanical prostheses-comprising bileaflet, caged ball, and tilting disc designs-present distinct clinical profiles that influence follow-up care and anticoagulation management, while tissue valves-spanning bovine, homograft, and porcine options-offer alternatives prioritising biocompatibility and reduced long-term anticoagulation requirements. These intrinsic device-level differences necessitate tailored evidence generation and clinician education to support appropriate patient selection and long-term management pathways.

Procedure segmentation further nuances go-to-market strategies as surgical replacement pathways, including minimally invasive and traditional sternotomy approaches, coexist with transcatheter valve replacement options executed via transapical and transfemoral access. Manufacturers must therefore calibrate their clinical trials, training programs, and delivery system designs to address access-specific technical constraints and operator preferences. Application-based perspectives focused on aortic, mitral, and tricuspid valve interventions require device optimisation for anatomical variability, durability demands, and imaging compatibility. Finally, end-user segmentation between ambulatory surgical centers and hospitals influences purchasing timelines, capital equipment considerations, and procedural throughput expectations, shaping sales cycles and service model requirements. Integrating these segmentation lenses enables more precise product positioning, evidence strategies, and commercial resource allocation.

Comprehensive regional insights that contrast regulatory complexity, adoption drivers, and commercial pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are a primary determinant of regulatory timelines, adoption rates, and commercial models, creating diverse pathways to market across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, mature clinical ecosystems and established reimbursement infrastructures facilitate rapid uptake of innovative valve technologies, while health systems increasingly emphasise outcomes and cost-effectiveness to guide procurement. Conversely, markets within Europe, Middle East & Africa feature heterogeneous regulatory environments and varied payer landscapes, requiring nuanced market entry strategies and locally generated clinical evidence to support adoption across sub-regions.

The Asia-Pacific region presents a dual opportunity set, characterised by large patient populations and rapidly expanding procedural capacity, alongside regulatory modernisation and growing investments in domestic manufacturing. Manufacturers aiming to scale in Asia-Pacific must develop culturally attuned clinician engagement programs, flexible pricing models, and supply chain solutions that address regional logistics. Across all regions, strategic alliances with clinical leaders, investments in local data generation, and adaptive commercial models will be critical to navigating differing regulatory expectations, reimbursement policies, and hospital procurement practices. A regionalised approach that balances global standards with local execution is therefore essential for sustainable growth.

In-depth view of how leading manufacturers are differentiating through innovation, partnerships, evidence generation, and supply chain excellence

Competitive dynamics among device manufacturers are increasingly defined by the integration of clinical evidence, supply chain resilience, and differentiated technology platforms. Leading firms are investing in next-generation leaflet materials, enhanced durability testing, and purpose-built delivery systems to address unmet clinical needs and expand indication sets. Strategic partnerships with imaging and navigation companies, as well as collaborations with academic centres, are accelerating iterative device improvements and facilitating earlier clinician adoption through training and proctoring programs.

Beyond product innovation, successful companies demonstrate robust post-market surveillance and patient follow-up frameworks that reinforce clinician confidence and support reimbursement dialogues. Operational excellence in manufacturing and quality assurance, combined with flexible commercial models-including capital-light service offerings and outcomes-based contracting pilots-further differentiates market leaders. As procurement teams increasingly prioritise total cost of care and long-term outcomes, companies that can align clinical evidence with economic arguments and reliable supply will secure stronger positioning in competitive tenders and hospital formularies.

Actionable recommendations for device developers and health system leaders to align innovation, supply resilience, evidence generation, and commercial agility

Industry leaders should pursue a set of actionable strategies that align R&D investment with clinical priorities, operational resilience, and commercial agility. First, prioritise modular valve and delivery platform development that allows incremental upgrades without requiring full procedural retraining, thereby accelerating clinician adoption and reducing lifecycle costs. Concurrently, invest in durable preclinical and real-world evidence programmes that measure patient-centric outcomes and long-term performance to support reimbursement and expanded indications.

Second, develop flexible manufacturing and sourcing strategies to mitigate trade policy and tariff risk, including assessing nearshoring and multi-sourcing options for critical components. Strengthen post-market surveillance and registries to provide transparent safety and performance data that drive payer and clinician confidence. Third, tailor commercial approaches to distinct end-user needs by offering training bundles and service models adapted to the workflows of ambulatory surgical centres and hospitals. Finally, cultivate strategic partnerships with imaging, navigation, and digital health companies to enhance procedural precision and enable integrated care pathways. By executing these priorities, organisations can enhance resilience, accelerate adoption, and demonstrate clear value to clinicians, patients, and payers.

Transparent research methodology describing clinician engagements, regulatory analysis, and evidence triangulation used to derive prosthetic valve insights

This research synthesises primary insights from clinician interviews, procurement stakeholder consultations, and device developer briefings, combined with a rigorous review of peer-reviewed clinical literature, regulatory filings, and procedural best-practice guidelines. Primary qualitative engagements targeted interventional cardiologists, cardiac surgeons, hospital procurement leaders, and clinical trialists to capture frontline perspectives on adoption barriers, training needs, and procedural outcomes. These direct inputs were complemented by an assessment of regulatory documents and published post-market surveillance data to validate performance narratives and safety profiles across valve types and procedural approaches.

Analytical methods included thematic coding of qualitative interviews, cross-validation of device performance claims against regulatory summaries, and scenario analysis to explore supply chain and tariff sensitivities. Wherever possible, evidence triangulation was used to reconcile clinician-reported experiences with registry publications and regulatory decisions. The methodology emphasises transparency in data sources and incorporates stakeholder validation to ensure that conclusions reflect real-world operational and clinical realities rather than solely promotional narratives.

Conclusive synthesis emphasising the strategic imperatives needed to translate technological promise into sustained clinical adoption and operational resilience

The convergence of device innovation, procedural expansion, and supply chain complexity is creating both significant opportunities and novel risks for organisations operating in the prosthetic heart valve domain. Durable technological improvements and expanding indications have the potential to improve patient outcomes and broaden therapy access, but realising those benefits requires disciplined evidence strategies, adaptive manufacturing, and clinician-focused deployment models. As trade policies and reimbursement frameworks evolve, a proactive posture that prioritises resilience and clear value articulation will be essential to maintain competitive positioning.

Looking ahead, stakeholders that integrate rigorous clinical evidence, flexible commercial models, and robust supply chain planning will be better positioned to capitalise on clinical advances while mitigating policy and market volatility. Cross-functional collaboration across clinical, regulatory, and commercial teams will be critical to translating innovation into sustained adoption and improved patient care. Ultimately, success will be defined by the ability to align technological promise with practical implementation strategies that deliver measurable benefits to patients and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prosthetic Heart Valves Market, by Valve Type

  • 8.1. Mechanical
    • 8.1.1. Bileaflet
    • 8.1.2. Caged Ball
    • 8.1.3. Tilting Disc
  • 8.2. Tissue
    • 8.2.1. Bovine
    • 8.2.2. Homograft
    • 8.2.3. Porcine

9. Prosthetic Heart Valves Market, by Procedure

  • 9.1. Surgical Replacement
    • 9.1.1. Minimally Invasive
    • 9.1.2. Traditional Sternotomy
  • 9.2. Transcatheter Valve Replacement
    • 9.2.1. Transapical
    • 9.2.2. Transfemoral

10. Prosthetic Heart Valves Market, by Application

  • 10.1. Aortic
  • 10.2. Mitral
  • 10.3. Tricuspid

11. Prosthetic Heart Valves Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals

12. Prosthetic Heart Valves Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Prosthetic Heart Valves Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Prosthetic Heart Valves Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Prosthetic Heart Valves Market

16. China Prosthetic Heart Valves Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 4C Medical Technologies, Inc.
  • 17.6. Abbott Laboratories
  • 17.7. Artivion, Inc.
  • 17.8. Boston Scientific Corporation
  • 17.9. Braile Biomedica Industria, Comercio e Representacoes S.A.
  • 17.10. Colibri Heart Valve, LLC
  • 17.11. Corcym S.r.l.
  • 17.12. Edwards Lifesciences Corporation
  • 17.13. Foldax, Inc.
  • 17.14. JenaValve Technology, Inc.
  • 17.15. Labcor Laboratorios Ltda.
  • 17.16. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.17. LivaNova PLC
  • 17.18. Medtronic plc
  • 17.19. Meril Life Sciences Private Limited
  • 17.20. MicroPort CardioFlow Medtech Corporation
  • 17.21. On-X Life Technologies, Inc.
  • 17.22. Symetis SA
  • 17.23. TTK Healthcare Limited
  • 17.24. Venus Medtech Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTHETIC HEART VALVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROSTHETIC HEART VALVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PROSTHETIC HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY BILEAFLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY BILEAFLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY BILEAFLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY CAGED BALL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY CAGED BALL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY CAGED BALL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TILTING DISC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TILTING DISC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TILTING DISC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY HOMOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY HOMOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY HOMOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY PORCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY PORCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRADITIONAL STERNOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRADITIONAL STERNOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRADITIONAL STERNOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSAPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSAPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSAPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MITRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MITRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY MITRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRICUSPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRICUSPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY TRICUSPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS PROSTHETIC HEART VALVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GCC PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 156. GCC PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 183. G7 PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 184. G7 PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. NATO PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 192. NATO PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 193. NATO PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL PROSTHETIC HEART VALVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA PROSTHETIC HEART VALVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA PROSTHETIC HEART VALVES MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA PROSTHETIC HEART VALVES MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA PROSTHETIC HEART VALVES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA PROSTHETIC HEART VALVES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA PROSTHETIC HEART VALVES MARKET SIZE, BY SURGICAL REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA PROSTHETIC HEART VALVES MARKET SIZE, BY TRANSCATHETER VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA PROSTHETIC HEART VALVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA PROSTHETIC HEART VALVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)